Aczone and Application site discoloration - a phase IV clinical study of FDA data

Summary:

Application site discoloration is reported as a side effect among people who take Aczone (dapsone), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Adderall, and have Acne cystic.

The phase IV clinical study analyzes which people have Application site discoloration when taking Aczone. It is created by eHealthMe based on reports of 1,126 people who have side effects when taking Aczone from the FDA, and is updated regularly.

What is Aczone?

Aczone has active ingredients of dapsone. It is often used in acne. eHealthMe is studying from 1,152 Aczone users. Check the latest studies of Aczone.

What is Application site discoloration?

Application site discoloration is found to be associated with 210 drugs and 446 conditions by eHealthMe. Check the latest studies of Application site discoloration.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

1,126 people reported to have side effects when taking Aczone.
Among them, 19 people (1.69%) have Application site discoloration.

Could Aczone cause Application site discoloration?

Among these 19 people:

How long have people been on Aczone when they have Application site discoloration? *

What is the gender of people who have Application site discoloration when taking Aczone? *

female: 75 %
male: 25 %

What is the age of people who have Application site discoloration when taking Aczone? *

What are other drugs people take besides Aczone? *

What are other side effects people have besides Application site discoloration? *

Application Site Pain: 2 people, 10.53%
Application Site Dryness: 2 people, 10.53%
Therapeutic Response Decreased (less preventive response): 1 person, 5.26%
Seborrhea: 1 person, 5.26%
Pigmentation Disorder (disturbances of human skin colour): 1 person, 5.26%
Chills (felling of cold): 1 person, 5.26%
Application Site Scar: 1 person, 5.26%
Application Site Pruritus (application site severe itching of the skin): 1 person, 5.26%
Application Site Irritation: 1 person, 5.26%
Application Site Erythema (redness of the skin at application site): 1 person, 5.26%

What are the existing conditions these people have? *

Acne Cystic (skin problems that cause pimples): 2 people, 10.53%
Stress And Anxiety: 1 person, 5.26%
Sleep Disorder: 1 person, 5.26%
Rashes (redness): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Aczone and have Application site discoloration?

- Check whether Application site discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aczone:

Aczone (1,152 reports)

Browse all side effects of Aczone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site discoloration:

Application site discoloration (210 drugs)

Browse all the conditions that are associated with Application site discoloration:

Application site discoloration (446 conditions)

Related publications that referenced our studies

Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dapsone (the active ingredients of Aczone) and Aczone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.